Combination therapy for EGFR-positive advanced penile cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your cancer has spread to other parts of the body and is a type called squamous cell carcinoma.
- A test has confirmed your tumor has the EGFR protein.
- You have at least one tumor that can be measured on a scan.
- You have already tried at least one type of chemotherapy, or you cannot tolerate chemotherapy.
- Your blood counts, liver, kidney, and thyroid function are within acceptable ranges.
- You have not had prior treatment with an antibody-drug conjugate like MMAE or a PD-(L)1 inhibitor.
- You do not have a history of certain autoimmune diseases, active infections, or uncontrolled health conditions.
- You have not had a live vaccine in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests two drugs given before surgery for penile cancer that has spread to nearby tissues or lymph nodes. The goal is to see if this combination can shrink tumors and improve outcomes. The drugs work by helping the immune system attack cancer cells and delivering chemotherapy directly to them.
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.